JP2007520539A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520539A5 JP2007520539A5 JP2006551908A JP2006551908A JP2007520539A5 JP 2007520539 A5 JP2007520539 A5 JP 2007520539A5 JP 2006551908 A JP2006551908 A JP 2006551908A JP 2006551908 A JP2006551908 A JP 2006551908A JP 2007520539 A5 JP2007520539 A5 JP 2007520539A5
- Authority
- JP
- Japan
- Prior art keywords
- depression
- disorder
- features
- disorders
- sleep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000025319 neurotic depression Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402357.8A GB0402357D0 (en) | 2004-02-03 | 2004-02-03 | Novel compounds |
| PCT/GB2005/000350 WO2005075464A1 (en) | 2004-02-03 | 2005-02-01 | Pyridine derivatives as connabinoid receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007520539A JP2007520539A (ja) | 2007-07-26 |
| JP2007520539A5 true JP2007520539A5 (cg-RX-API-DMAC10.html) | 2008-03-21 |
Family
ID=31985569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551908A Withdrawn JP2007520539A (ja) | 2004-02-03 | 2005-02-01 | カンナビノイド受容体モジュレーターとしてのピリジン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080280952A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1735301A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2007520539A (cg-RX-API-DMAC10.html) |
| GB (1) | GB0402357D0 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2005075464A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
| JP2009538933A (ja) | 2006-05-31 | 2009-11-12 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての化合物およびその使用 |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| US7691863B2 (en) | 2006-10-04 | 2010-04-06 | Hoffman-La Roche Inc. | Pyrazine-2-carboxamide derivatives as CB2 receptor modulators |
| CN101765594A (zh) | 2007-03-28 | 2010-06-30 | 雅培制药有限公司 | 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物 |
| US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| WO2008144360A1 (en) | 2007-05-18 | 2008-11-27 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
| US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US8188135B2 (en) | 2008-09-16 | 2012-05-29 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
| WO2010113834A1 (ja) | 2009-03-30 | 2010-10-07 | アステラス製薬株式会社 | ピリミジン化合物 |
| WO2012052167A1 (en) * | 2010-10-20 | 2012-04-26 | Grünenthal GmbH | Substituted 6-amino-nicotinamides as kcnq2/3 modulators |
| US10963104B2 (en) | 2017-02-06 | 2021-03-30 | Flatfrog Laboratories Ab | Optical coupling in touch-sensing systems |
| US11256371B2 (en) | 2017-09-01 | 2022-02-22 | Flatfrog Laboratories Ab | Optical component |
| WO2019172826A1 (en) | 2018-03-05 | 2019-09-12 | Flatfrog Laboratories Ab | Improved touch-sensing apparatus |
| CN112889016A (zh) | 2018-10-20 | 2021-06-01 | 平蛙实验室股份公司 | 用于触摸敏感装置的框架及其工具 |
| CN114730228A (zh) | 2019-11-25 | 2022-07-08 | 平蛙实验室股份公司 | 一种触摸感应设备 |
| WO2021158164A1 (en) | 2020-02-08 | 2021-08-12 | Flatfrog Laboratories Ab | Touch apparatus with low latency interactions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| GB0222495D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
-
2004
- 2004-02-03 GB GBGB0402357.8A patent/GB0402357D0/en not_active Ceased
-
2005
- 2005-02-01 US US10/597,474 patent/US20080280952A1/en not_active Abandoned
- 2005-02-01 EP EP05702090A patent/EP1735301A1/en not_active Withdrawn
- 2005-02-01 WO PCT/GB2005/000350 patent/WO2005075464A1/en not_active Ceased
- 2005-02-01 JP JP2006551908A patent/JP2007520539A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520539A5 (cg-RX-API-DMAC10.html) | ||
| JP2008501758A5 (cg-RX-API-DMAC10.html) | ||
| JP2003511434A (ja) | モノアミン再取込み阻害剤として有用な新規ビアリールエーテル誘導体 | |
| JP2007523206A5 (cg-RX-API-DMAC10.html) | ||
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| WO2007099423A1 (en) | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists | |
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2013540794A (ja) | 疼痛、精神病性障害、認知障害、またはアルツハイマー病の治療のためのアルファ‐７ニコチン性受容体修飾薬 | |
| JP2020502092A5 (cg-RX-API-DMAC10.html) | ||
| CA2702482A1 (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| RU2009136330A (ru) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора | |
| WO2009109493A3 (en) | 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists | |
| JP2005523335A5 (cg-RX-API-DMAC10.html) | ||
| JP2007523207A5 (cg-RX-API-DMAC10.html) | ||
| RU2009142997A (ru) | 4-алкоксипиридазиновые производные в качестве быстро диссоциирующихся антагонистов рецептора 2 допамина | |
| DK2614824T3 (en) | TRIAZOLD DERIVATIVES TO USE IN THE TREATMENT OF NEUROPATHIC PAIN AND FIBROMYALGIA | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| NO20092688L (no) | Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering | |
| KR20070086598A (ko) | 아릴- 및 헤테로아릴-치환 테트라히드로이소퀴놀린과노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 이의 용도 | |
| JP2007529495A5 (cg-RX-API-DMAC10.html) | ||
| JP2007520537A5 (cg-RX-API-DMAC10.html) | ||
| JP2006502157A5 (cg-RX-API-DMAC10.html) | ||
| JP2009518337A5 (cg-RX-API-DMAC10.html) | ||
| CN101605793B (zh) | 氮杂双环链烷衍生物、它们的制备与治疗应用 | |
| MX2010008239A (es) | 2-aminoquinolinas. |